Actively Recruiting
Correction of Psoriatic T Cell Signatures by Deucravacitinib
Led by University of California, San Francisco · Updated on 2024-06-27
25
Participants Needed
1
Research Sites
139 weeks
Total Duration
On this page
Sponsors
U
University of California, San Francisco
Lead Sponsor
B
Bristol-Myers Squibb
Collaborating Sponsor
AI-Summary
What this Trial Is About
This study aims to assess cutaneous and blood immune cell function of patients with psoriasis before and after initiation of treatment with the Tyrosine kinase 2 (TYK2) blocker, deucravacitinib.
CONDITIONS
Official Title
Correction of Psoriatic T Cell Signatures by Deucravacitinib
Who Can Participate
Eligibility Criteria
You may qualify if you...
- 18 years of age or older
- Diagnosis of moderate to severe psoriasis with body surface area equal to or greater than 10%, PASI score equal to or greater than 12, and static Physician's Global Assessment of 3 or above
You will not qualify if you...
- Use of systemic immunosuppressive drugs within the last 12 weeks
- Pregnancy
- Severe immunodeficiency from genetic or infectious causes
- Active tuberculosis or other serious infections
- Active systemic cancer
- Breastfeeding
- Any condition or abnormality that may compromise safety or data quality as determined by the investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University of California, San Francisco
San Francisco, California, United States, 94115
Actively Recruiting
Research Team
R
Raymond Cho, MD, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
BASIC_SCIENCE
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here